Intercept Pharmaceuticals - ICPT Stock Price Target and Predictions

  • Consensus Rating: Hold
  • Consensus Price Target: $19.00
  • Forecasted Upside: 0.00%
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 4 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
+0 (0.00%)
Get New Intercept Pharmaceuticals Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for ICPT and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for ICPT

Analyst Price Target is $19.00
This price target is based on 4 analysts offering 12 month price targets for Intercept Pharmaceuticals in the last 3 months. The average price target is $19.00, with a high forecast of $19.00 and a low forecast of $19.00. The average price target represents a 0.00% upside from the last price of $19.00.

This chart shows the closing price for ICPT for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 4 contributing investment analysts is to hold stock in Intercept Pharmaceuticals. This Hold consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
9/27/2023Royal Bank of CanadaBoost TargetSector Perform ➝ Sector Perform$12.00 ➝ $19.00Low
9/27/2023Canaccord Genuity GroupReiterated RatingBuy ➝ Hold$20.00 ➝ $19.00Low
9/27/2023HC WainwrightDowngradeBuy ➝ Neutral$19.00Low
9/26/2023B. RileyDowngradeBuy ➝ Neutral$15.00 ➝ $19.00N/A
8/3/2023Canaccord Genuity GroupBoost TargetBuy ➝ Buy$19.00 ➝ $20.00Low
8/3/2023HC WainwrightReiterated RatingBuy$19.00Low
7/13/2023HC WainwrightUpgradeSell ➝ Buy$8.00 ➝ $19.00Low
6/29/2023Canaccord Genuity GroupUpgradeHold ➝ Buy$12.00 ➝ $18.00Low
6/26/2023Royal Bank of CanadaLower Target$14.00 ➝ $13.00Low
5/30/2023B. RileyLower Target$30.00 ➝ $15.00Low
5/23/2023Bank of AmericaLower Target$17.00 ➝ $14.00Low
5/23/2023Needham & Company LLCDowngradeBuy ➝ HoldLow
5/22/2023Robert W. BairdLower Target$35.00 ➝ $18.00Low
5/22/2023HC WainwrightDowngradeNeutral ➝ Sell$8.00Low
5/17/2023Raymond JamesDowngradeOutperform ➝ Market PerformLow
4/28/2023Raymond JamesBoost Target$28.00 ➝ $31.00Low
4/10/2023Piper SandlerBoost TargetOverweight$49.00 ➝ $54.00Low
3/5/2023Raymond JamesBoost TargetOutperform$26.00 ➝ $28.00Low
3/3/2023SVB LeerinkBoost TargetMarket Perform$17.00 ➝ $18.00Low
3/3/2023SVB SecuritiesBoost Target$17.00 ➝ $18.00Low
3/3/2023Royal Bank of CanadaBoost TargetSector Perform$17.00 ➝ $19.00Low
3/3/2023Needham & Company LLCBoost TargetBuy$22.00 ➝ $26.00Low
2/15/2023Royal Bank of CanadaBoost TargetSector Perform$15.00 ➝ $18.00Low
1/20/2023Raymond JamesLower TargetOutperform$27.00 ➝ $26.00Low
11/16/2022HC WainwrightLower TargetNeutral$16.00 ➝ $14.00Low
10/3/2022Robert W. BairdLower TargetOutperform$52.00 ➝ $35.00Low
10/3/2022SVB LeerinkLower TargetMarket Perform$21.00 ➝ $17.00Low
9/30/2022Piper SandlerLower Target$82.00 ➝ $49.00Low
8/22/2022B. RileyLower TargetBuy$30.00 ➝ $28.00Low
8/9/2022CowenLower Target$22.00Low
8/8/2022HC WainwrightLower TargetNeutral$18.00 ➝ $16.00Low
8/4/2022Raymond JamesBoost TargetOutperform$23.00 ➝ $26.00N/A
7/8/2022SVB LeerinkLower TargetMarket Perform$27.00 ➝ $21.00N/A
7/8/2022Needham & Company LLCLower TargetBuy$25.00 ➝ $22.00N/A
5/10/2022B. RileyBoost Target$30.00 ➝ $32.00Low
5/9/2022Raymond JamesLower Target$44.00 ➝ $23.00Medium
3/8/2022Canaccord Genuity GroupLower TargetHold$31.00 ➝ $29.00Low
3/3/2022Royal Bank of CanadaLower TargetSector Perform$22.00 ➝ $16.00High
3/3/2022Needham & Company LLCLower TargetBuy$30.00 ➝ $25.00Medium
3/3/2022SVB LeerinkLower TargetMarket Perform$30.00 ➝ $27.00Medium
1/10/2022B. RileyUpgradeNeutral ➝ Buy$25.00 ➝ $30.00High
11/8/2021BMO Capital MarketsReiterated RatingHold$22.00Low
11/5/2021Jefferies Financial GroupReiterated RatingHold$19.00Medium
11/4/2021B. RileyBoost TargetNeutral$22.00 ➝ $25.00High
11/4/2021Raymond JamesBoost TargetOutperform$40.00 ➝ $44.00Medium
8/20/2021The Goldman Sachs GroupDowngradeNeutral ➝ Sell$17.00 ➝ $10.00Low
8/3/2021B. RileyBoost TargetNeutral$18.00 ➝ $22.00High
8/2/2021WedbushLower TargetOutperform$74.00 ➝ $67.00Low
8/2/2021HC WainwrightReiterated RatingNeutral$21.00 ➝ $18.00Low
8/1/2021Robert W. BairdReiterated RatingBuy$52.00Low
7/30/2021Royal Bank of CanadaBoost TargetSector Perform$22.00 ➝ $23.00Low
5/31/2021SVB LeerinkReiterated RatingHoldLow
5/27/2021JMP SecuritiesReiterated RatingHoldLow
5/25/2021B. RileyDowngradeBuy ➝ Neutral$65.00 ➝ $18.00High
5/10/2021OppenheimerLower Target$33.00 ➝ $20.00Medium
5/7/2021The Goldman Sachs GroupLower TargetNeutral$29.00 ➝ $18.00Medium
5/7/2021Raymond JamesLower TargetOutperform$52.00 ➝ $40.00Low
5/7/2021BMO Capital MarketsLower TargetMarket Perform$29.00 ➝ $19.00Low
5/7/2021Cantor FitzgeraldLower TargetNeutral$45.00 ➝ $23.00Low
5/6/2021Stifel NicolausLower TargetHold$29.00 ➝ $16.00Low
3/12/2021HC WainwrightUpgradeSell ➝ Neutral$25.00 ➝ $21.00Medium
3/2/2021Needham & Company LLCLower TargetBuy$80.00 ➝ $34.00Medium
3/1/2021WedbushLower TargetOutperform$106.00 ➝ $88.00Low
3/1/2021B. RileyLower TargetBuy$74.00 ➝ $65.00Low
3/1/2021HC WainwrightReiterated RatingNeutral ➝ Sell$25.00Low
3/1/2021Chardan CapitalLower TargetBuy$58.00 ➝ $45.00Low
2/26/2021Raymond JamesLower TargetOutperform$60.00 ➝ $52.00High
2/23/2021HC WainwrightDowngradeNeutral ➝ Sell$25.00Low
1/19/2021WedbushLower TargetOutperform$116.00 ➝ $106.00Low
1/15/2021Bank of AmericaDowngradeNeutral ➝ Underperform$40.00 ➝ $27.00High
12/21/2020Jefferies Financial GroupDowngradeBuy ➝ Hold$30.00Low
11/20/2020B. RileyLower TargetBuy$97.00 ➝ $74.00High
11/10/2020BMO Capital MarketsLower TargetMarket Perform$56.00 ➝ $38.00High
11/10/2020Royal Bank of CanadaLower TargetSector Perform$49.00 ➝ $40.00High
11/10/2020Credit Suisse GroupLower TargetHold ➝ Neutral$60.00 ➝ $42.00High
11/10/2020Robert W. BairdUpgradeNeutral ➝ Outperform$52.00High
11/10/2020Raymond JamesUpgradeMarket Perform ➝ Outperform$60.00High
11/10/2020SVB LeerinkLower TargetMarket Perform$50.00 ➝ $48.00High
11/10/2020Chardan CapitalLower TargetBuy$105.00 ➝ $58.00High
8/28/2020WedbushReiterated RatingBuy$140.00Medium
8/11/2020Royal Bank of CanadaReiterated RatingHold$57.00Low
8/11/2020OppenheimerReiterated RatingHold$54.00Medium
8/11/2020Chardan CapitalReiterated RatingBuy$105.00Medium
8/10/2020Needham & Company LLCInitiated CoverageBuy$100.00Medium
8/10/2020B. RileyReiterated RatingBuy$97.00Medium
8/10/2020Stifel NicolausBoost TargetHold$51.00 ➝ $56.00High
7/30/2020Piper SandlerInitiated CoverageOverweight$82.00Medium
7/21/2020JMP SecuritiesDowngradeOutperform ➝ Market PerformLow
6/30/2020Chardan CapitalReiterated RatingBuy$105.00Low
6/30/2020CitigroupUpgradeNeutral ➝ Buy$110.00 ➝ $67.00High
6/30/2020SVB LeerinkLower TargetMarket Perform$89.00 ➝ $50.00Low
6/30/2020Needham & Company LLCLower TargetBuy$150.00 ➝ $100.00Low
6/30/2020UBS GroupDowngradeBuy ➝ Neutral$135.00 ➝ $57.00Medium
6/30/2020Robert W. BairdDowngradeOutperform ➝ Neutral$52.00Medium
6/30/2020Cantor FitzgeraldDowngradeOverweight ➝ Neutral$57.00Medium
6/29/2020B. RileyReiterated RatingBuy$97.00Medium
6/29/2020WedbushReiterated RatingBuy$140.00Medium
6/29/2020Credit Suisse GroupDowngradeOutperform ➝ Neutral$137.00 ➝ $59.00Medium
6/29/2020CowenDowngradeOutperform ➝ Market Perform$149.00 ➝ $47.00Medium
6/29/2020Raymond JamesDowngradeOutperform ➝ Market PerformHigh
6/29/2020Stifel NicolausLower TargetHold$100.00 ➝ $51.00High
6/29/2020The Goldman Sachs GroupDowngradeBuy ➝ Neutral$150.00 ➝ $60.00High
6/29/2020BMO Capital MarketsDowngradeOutperform ➝ Market Perform$107.00 ➝ $52.00High
6/29/2020Royal Bank of CanadaDowngradeOutperform ➝ Sector Perform$117.00 ➝ $55.00Medium
6/29/2020OppenheimerDowngradeOutperform ➝ Market Perform$124.00 ➝ $46.00High
6/29/2020Wells Fargo & CompanyDowngradeOverweight ➝ Equal Weight$146.00 ➝ $46.00High
6/25/2020HC WainwrightInitiated CoverageNeutral$92.00Medium
6/4/2020BMO Capital MarketsInitiated CoverageOutperform$107.00Low
5/22/2020Robert W. BairdReiterated RatingBuy$227.00High
5/22/2020B. RileyReiterated RatingBuy$158.00N/A
5/22/2020Raymond JamesDowngradeStrong-Buy ➝ Outperform$145.00 ➝ $115.00High
5/14/2020WedbushReiterated RatingBuy$257.00Medium
5/13/2020B. RileyReiterated RatingBuy$158.00High
5/12/2020Chardan CapitalReiterated RatingBuy$145.00High
5/12/2020Stifel NicolausLower TargetHold$100.00 ➝ $99.00Medium
5/12/2020CitigroupDowngradeBuy ➝ Neutral$110.00Medium
5/11/2020Needham & Company LLCReiterated RatingBuy$150.00High
4/27/2020WedbushReiterated RatingBuy$257.00High
4/8/2020Royal Bank of CanadaReiterated RatingBuy$117.00High
4/2/2020Chardan CapitalInitiated CoverageBuy$145.00Low
3/26/2020WedbushReiterated RatingBuy$257.00High
3/26/2020B. RileyReiterated RatingBuy$158.00High
3/5/2020Bank of AmericaInitiated CoverageNeutral$111.00Low
2/27/2020WedbushReiterated RatingBuy$257.00High
2/26/2020Cantor FitzgeraldReiterated RatingBuy$186.00High
2/26/2020OppenheimerLower Target$146.00 ➝ $124.00Low
2/26/2020CitigroupUpgradeNeutral ➝ Buy$140.00 ➝ $125.00High
2/20/2020B. RileyReiterated RatingBuy$158.00N/A
2/10/2020WedbushReiterated RatingBuy$257.00Medium
1/29/2020WedbushReiterated RatingBuy$257.00Low
1/22/2020WedbushReiterated RatingBuy$257.00Medium
1/9/2020B. RileyBoost TargetBuy$133.00 ➝ $158.00Low
1/2/2020SVB LeerinkReiterated RatingUnderperformMedium
1/2/2020CitigroupDowngradeBuy ➝ Neutral$85.00 ➝ $140.00High
12/18/2019WedbushReiterated RatingBuy$257.00Low
12/17/2019Robert W. BairdReiterated RatingBuy$227.00Low
12/17/2019Needham & Company LLCReiterated RatingBuy$150.00Low
12/17/2019Credit Suisse GroupReiterated RatingOutperform$87.00 ➝ $141.00Low
12/17/2019Wells Fargo & CompanyReiterated RatingPositive ➝ Overweight$120.00 ➝ $146.00Low
12/13/2019B. RileyReiterated RatingBuy$133.00High
11/25/2019Robert W. BairdReiterated RatingBuy$227.00High
11/25/2019Stifel NicolausBoost Target$86.00 ➝ $102.00High
11/5/2019WedbushReiterated RatingBuy$243.00High
11/5/2019Needham & Company LLCReiterated RatingBuy$150.00Low
10/21/2019Raymond JamesLower TargetStrong-Buy$148.00 ➝ $147.00High
10/18/2019Jefferies Financial GroupSet TargetBuy$125.00High
10/18/2019Credit Suisse GroupLower Target$167.00 ➝ $87.00Low
9/30/2019WedbushSet TargetBuy$243.00Low
9/6/2019Royal Bank of CanadaSet TargetBuy$135.00Medium
9/4/2019CitigroupUpgradeNeutral ➝ Buy$106.00 ➝ $85.00Medium
8/23/2019Raymond JamesSet TargetBuy$148.00N/A
8/12/2019Stifel NicolausReiterated RatingHold$86.00Low
8/8/2019Royal Bank of CanadaReiterated RatingBuy$135.00Medium
8/8/2019Cantor FitzgeraldLower TargetOverweight$191.00 ➝ $186.00High
8/7/2019Raymond JamesSet TargetBuy$149.00Medium
8/6/2019OppenheimerLower TargetOutperform$170.00 ➝ $160.00Medium
(Data available from 7/19/2019 forward)

News Sentiment Rating

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Current Sentiment

  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.


  • No negative mentions tracked during this time.


  • No positive mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Intercept Pharmaceuticals logo
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development. The company has a license agreement with Aralez Pharmaceuticals Canada Inc. to develop and commercialize bezafibrate in the United States. It markets its products through an internal commercial organization and third-party distributors. The company was incorporated in 2002 and is headquartered in Morristown, New Jersey. As of November 8, 2023, Intercept Pharmaceuticals, Inc. operates as a subsidiary of Alfasigma S.p.A..
Read More

Today's Range

Now: $19.00
Low: $19.00
High: $19.00

50 Day Range

MA: $18.88
Low: $18.20
High: $19.00

52 Week Range

Now: $19.00
Low: $8.82
High: $21.86



Average Volume

1,362,029 shs

Market Capitalization

$794.77 million

P/E Ratio


Dividend Yield




Frequently Asked Questions

What sell-side analysts currently cover shares of Intercept Pharmaceuticals?

The following Wall Street analysts have issued reports on Intercept Pharmaceuticals in the last twelve months: B. Riley, Canaccord Genuity Group Inc., HC Wainwright, Royal Bank of Canada, and
View the latest analyst ratings for ICPT.

What is the current price target for Intercept Pharmaceuticals?

4 Wall Street analysts have set twelve-month price targets for Intercept Pharmaceuticals in the last year. Their average twelve-month price target is $19.00. Royal Bank of Canada has the highest price target set, predicting ICPT will reach $19.00 in the next twelve months. Royal Bank of Canada has the lowest price target set, forecasting a price of $19.00 for Intercept Pharmaceuticals in the next year.
View the latest price targets for ICPT.

What is the current consensus analyst rating for Intercept Pharmaceuticals?

Intercept Pharmaceuticals currently has 4 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in ICPT, but not buy more shares or sell existing shares.
View the latest ratings for ICPT.

What other companies compete with Intercept Pharmaceuticals?

How do I contact Intercept Pharmaceuticals' investor relations team?

Intercept Pharmaceuticals' physical mailing address is 10 Hudson Yards 37th FL, New York NY, 10001. The biopharmaceutical company's listed phone number is (646) 747-1000 and its investor relations email address is [email protected]. The official website for Intercept Pharmaceuticals is Learn More about contacing Intercept Pharmaceuticals investor relations.